09:33 AM EDT, 06/13/2024 (MT Newswires) -- Replimune Group ( REPL ) said Thursday it has entered into a $100 million private investment in public equity transaction agreement led by an unnamed life-sciences-focused institutional investor.

The deal also attracted the Redmile Group, RTW Investments, Boxer Capital and other institutional investors, including a leading mutual fund.

Under the terms of the PIPE purchase agreement, Replimune ( REPL ) will issue and sell nearly 5.7 million common shares, together with an equal number of pre-funded warrants, all priced at $8.82 apiece. The deal is expected to close on Friday, subject to satisfaction of customary conditions.

Replimune ( REPL ) is expecting to use the transaction net proceeds to fully scale the commercialization of its RP1 therapy candidate to treat skin cancers as well as working capital and general corporate purposes. The company plans on filing a biologics licence application for RP1 during the second half of 2024.

Price: 8.61, Change: -0.21, Percent Change: -2.38